Indivior Pharmaceuticals, Inc. Expense Breakdown
No Expense Breakdown for INDV on this site yet.
- 2026-06-30: Reportable $50.00M.
- 2025-06-30: Reportable $52.00M.
Source checked: the stored Expense Breakdown page for INDV.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $50.00M |
|---|
| 2025-06-30 | $52.00M |
|---|
Depreciation, Depletion and Amortization: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $2.00M |
|---|
| 2025-06-30 | $3.00M |
|---|
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $38.00M |
|---|
| 2025-06-30 | $44.00M |
|---|
Operating expenses: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $134.00M |
|---|
| 2025-06-30 | $179.00M |
|---|
Research and Development Expense (Excluding Acquired in Process Cost): each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $12.00M |
|---|
| 2025-06-30 | $21.00M |
|---|
Selling, General and Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $122.00M |
|---|
| 2025-06-30 | $158.00M |
|---|
Share-based Payment Arrangement, Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|
| 2026-06-30 | $11.00M |
|---|
| 2025-06-30 | $8.00M |
|---|